Tareen Basir, Godoy Guilherme, Sankin Alex, Temkin Steve, Lepor Herbert, Taneja Samir S
Division of Urologic Oncology, New York University School of Medicine, New York, NY 10016, USA.
BJU Int. 2009 Jul;104(2):195-9. doi: 10.1111/j.1464-410X.2009.08347.x. Epub 2009 Feb 3.
To determine if biopsy characteristics can be used to identify men with unilateral prostate cancer on radical prostatectomy (RP) pathological specimens, thereby selecting candidates for hemi-ablative focal therapy.
Of 1458 men who had RP from January 2000 to June 2007, we identified 590 of 880 evaluable patients with unilateral disease on their preoperative biopsy. Charts were reviewed to record preoperative prostate-specific antigen (PSA) level, high-grade prostatic intraepithelial neoplasia (HGPIN), clinical stage, Gleason score, perineural invasion (PNI), prostate volume, number of positive cores, and percentage of positive cores. Final surgical pathology was evaluated for unilateral cancer. Univariate analysis was used (logistic regression method) to identify independent predictors of unilateral disease on the RP specimen. A subset analysis was done in men with low-risk disease, defined as clinical stage T1C, Gleason score <7 and a PSA level of <10 ng/mL.
Of 590 men with unilateral disease on biopsy, 163 (27.3%) had unilateral disease on the RP specimen. Pathological features, including HGPIN (P = 0.714), Gleason score (P > 0.608), PNI (P = 0.714), number of positive cores (P = 0.076), percentage of cores positive (P = 0.056), prostate volume (P = 0.285), and PSA level (P = 0.062) did not improve the prediction of unilateral disease. When men with unilateral cancer were further stratified to include only those with low-risk disease, 28.4% had unilateral disease on the RP specimen. None of the biopsy or clinical features evaluated were predictors of unilateral disease on the RP specimen.
Unilateral prostate cancer on biopsy predicts unilateral disease on RP pathology in only 27.6% of cases. The predictive ability is not improved by adding biopsy and clinical characteristics. Additional methods are needed to accurately identify men appropriate for focal therapy.
确定活检特征是否可用于在根治性前列腺切除术(RP)病理标本上识别单侧前列腺癌男性患者,从而筛选出适合半消融性聚焦治疗的候选者。
在2000年1月至2007年6月期间接受RP的1458名男性中,我们在880例可评估的术前活检为单侧疾病的患者中确定了590例。查阅病历以记录术前前列腺特异性抗原(PSA)水平、高级别前列腺上皮内瘤变(HGPIN)、临床分期、Gleason评分、神经周围侵犯(PNI)、前列腺体积、阳性活检芯数量及阳性活检芯百分比。对最终手术病理进行单侧癌评估。采用单因素分析(逻辑回归法)确定RP标本上单侧疾病的独立预测因素。对定义为临床分期T1C、Gleason评分<7且PSA水平<10 ng/mL的低风险疾病男性进行亚组分析。
在590例活检为单侧疾病的男性中,163例(27.3%)在RP标本上为单侧疾病。病理特征,包括HGPIN(P = 0.714)、Gleason评分(P > 0.608)、PNI(P = 0.714)、阳性活检芯数量(P = 0.076)、活检芯阳性百分比(P = 0.056)、前列腺体积(P = 0.285)和PSA水平(P = 0.062)均未改善对单侧疾病的预测。当将单侧癌男性进一步分层仅纳入低风险疾病患者时,28.4%在RP标本上为单侧疾病(P = 0.714)。所评估的活检或临床特征均不是RP标本上单侧疾病的预测因素。
活检时的单侧前列腺癌仅在27.6%的病例中预测RP病理上的单侧疾病。增加活检和临床特征并不能提高预测能力。需要其他方法来准确识别适合聚焦治疗的男性。